ライフサイエンスコーパス: antigenemia

1 ereas 18 had cleared both microfilaremia and antigenemia.

2 dictive values for the detection of CMV pp65 antigenemia.

3 treated preemptively for the first positive antigenemia.

4 given either at engraftment or for CMV pp65 antigenemia.

5 ing antibodies in plasma, and high levels of antigenemia.

6 odies; and had low or undetectable levels of antigenemia.

7 ed with clinically detectable HBV disease or antigenemia.

8 fferent levels of CMV virus load measured by antigenemia.

9 , dual CMV-CTLs were not associated with CMV antigenemia.

10 monkeys, 2 having delayed onset and peak of antigenemia.

11 to anticytomegalovirus therapy or low-level antigenemia.

12 ssed the onset or level of chronic rotavirus antigenemia.

13 specimens and a latex agglutination test for antigenemia.

14 ee Plasma-Lyte resulted in positive serum GM antigenemia.

15 serum antibodies are essential for resolving antigenemia.

16 gs, confirming previous reports of rotavirus antigenemia.

17 ed by blood-borne microfilariae and filarial antigenemia.

18 sults in 30 (77%) of 39 episodes detected by antigenemia.

19 ecificity, and predictive values compared to antigenemia: 122 of 151 antigenemia-positive samples wer

20 V-coinfected; 135 had persistent HBV surface antigenemia, 1374 had resolved HBV infection, and 287 we

21 ood samples tested for cytomegalovirus (CMV) antigenemia, 18 (16.5%) were positive.

22 re also higher in subjects experiencing late antigenemia (2.4% vs 0.57%).

23 8.1-fold (95% CI, 1.9-35.2) with HBV surface antigenemia, 2.1-fold (95% CI, 1.3-3.3) with fewer than

24 those with HCV (3.4) or hepatitis B surface antigenemia (6.5).

25 Sixty-four individuals (58%) developed p24 antigenemia a median of 11.6 years after seroconversion.

26 nciclovir use, HLA matching, circulating CMV antigenemia, absolute CD4+ and CD8+ counts, and donor CM

27 or cytomegalovirus (CMV) by culture and pp65 antigenemia across four test sites.

28 2), and monitored for microfilaria, parasite antigenemia, adverse events (AEs), and serum drug levels

29 isease before or during the first episode of antigenemia and 6 (5.3%) developed disease after discont

30 at is significantly more sensitive than pp65 antigenemia and blood cultures for detection of CMV in b

31 The percentage of positive antigenemia and CMV disease was 55 and 8%, respectively.

32 patients had persistently elevated levels of antigenemia and CMV DNA by PCR when resistance to gancic

33 were compared by cytomegalovirus (CMV) pp65 antigenemia and CMV infectivity on the day of sample col

34 A significant relationship between p24 antigenemia and death was nonsignificant after adjusting

35 ing the start of ganciclovir until highgrade antigenemia and discontinuing ganciclovir based on negat

36 ients, there was a corresponding increase in antigenemia and leukopenia.

37 B delta Sp1234 showed lower levels of plasma antigenemia and lower virus burdens; the other animal in

38 The relationship between filarial antigenemia and lymphatic pathology was investigated in

39 ts, there was a good association between the antigenemia and PCR assays.

40 rt demonstrating that clearance of rotavirus antigenemia and possibly viremia are mediated by multipl

41 d for at least 3 weeks or until negative CMV antigenemia and resumed only if antigenemia recurred.

42 with the evidence of the persistent SIV p27 antigenemia and SIVmac-induced disease.

43 tients were monitored posttransplantation by antigenemia and TaqMan CMV QPCR.

44 reactivation in 28 patients were detected by antigenemia and treated by antiviral drugs.

45 positive for CMV, 106 (97%) were positive by antigenemia, and 34 (31%) were positive by culture.

46 (PBMC), quantitate gene expression, measure antigenemia, and determine nitric oxide levels.

47 ncy and the CD4 count, human cytomegalovirus antigenemia, and other risk factors for adrenal insuffic

48 All results of CMV PCR and/or pp65 antigenemia, and pathological reports were reviewed.

49 ients (64%) became positive by PBL PCR, pp65 antigenemia, and plasma PCR.

50 s), the leukocyte fraction was tested by CMV antigenemia, and quantitative PCR was performed on plasm

51 s in CD4+ cell counts, the highest levels of antigenemia, and the greatest expression of viral RNA an

52 ecting CMV infection, but that the degree of antigenemia as expressed by the number of positive cells

53 We compared the antigenemia assay (AA) with tandem shell vial cultures (

54 ture and an established cytomegalovirus pp65 antigenemia assay (CMV AG).

55 o the eye examinations were 80% for the pp65 antigenemia assay (cutoff, >0 cell per 1.5 x 10(5) leuko

56 UL55/UL123-exon 4) were compared to the pp65 antigenemia assay and blood cultures.

57 Recent diagnostic advances, such as the CMV antigenemia assay and CMV-DNA detection by polymerase ch

58 OR CMV Test was compared to those of the CMV antigenemia assay and the conventional tube culture meth

59 lue were 70.5, 97.5, 87.8, and 92.8% for the antigenemia assay and were 96.7, 92.0, 75.6, and 99.1% f

60 In 49 specimens, PBL PCR and/or pp65 antigenemia assay could not be performed because of insu

61 Sens CMV pp67 tests were compared to the CMV antigenemia assay for 45 transplant recipients and 1 pat

62 MV) DNA in plasma is less sensitive than the antigenemia assay for CMV surveillance in blood.

63 requently in blood specimens than either the antigenemia assay or cultures, but of the three PCR assa

64 ective study, the cytomegalovirus (CMV) pp65 antigenemia assay was compared with detection of CMV by

65 CR assay, and the cytomegalovirus (CMV) pp65 antigenemia assay was evaluated in transplant recipients

66 V Test, 21 (19%) of the specimens by the CMV antigenemia assay, and 10 (9%) of the specimens by cultu

67 ral blood leukocytes (PBL PCR), the CMV pp65 antigenemia assay, and viral cultures from blood, urine,

68 assay (MTP-PCR) and a semiquantitative pp65 antigenemia assay, each specimen was measured for HCMV l

69 he most sensitive test, followed by the pp65 antigenemia assay, plasma PCR, and viremia.

70 nc.) were tested in the cytomegalovirus pp65 antigenemia assay, to determine if whole-blood processin

71 to those of the more technically cumbersome antigenemia assay.

72 t of PBL PCR but similar to that of the pp65 antigenemia assay.

73 underwent weekly surveillance using the pp65 antigenemia assay.

74 Four commercial BG antigenemia assays are available (Fungitell, Fungitec-G,

75 Studies reporting the performance of BG antigenemia assays for the diagnosis of IFI (European Or

76 Two consecutive positive antigenemia assays have very high specificity, positive

77 Cytomegalovirus (CMV) antigenemia assays were positive in 27% of the patients,

78 Plasma antigenemia at 2 weeks after inoculation (P < or = 0.002

79 0 (50%) of 20 patients with asymptomatic CMV antigenemia at different levels.

80 te form of the disease showed rapid falls in antigenemia, becoming antigen negative by week 14 (range

81 Prevalence of antigenemia by village ranged from 61.7% to 98.2% and di

82 Pre-emptive prophylaxis based on CMV antigenemia can effectively target the patients for CMV

83 splantation, preceding detection of CMV pp65 antigenemia, CD4 T-cell counts lower than 50 cells/mm(3)

84 conventional cell culture (TC-CPE), the CMV-antigenemia (CMV-Ag) assay, one or more in-house CMV nes

85 el of CCIC in patients with asymptomatic CMV antigenemia, CMV pneumonia with or without copathogen, o

86 ill significantly higher among patients with antigenemia count >11 leukocytes (adjusted RR = 4.9, 95%

87 of CMV disease compared to patients with an antigenemia count < or =11 leukocytes (RR = 7.3, 95% con

88 rtional hazards model, patients with a first antigenemia count of >11 leukocytes had a significantly

89 tive recipients were treated only when their antigenemia count reached a threshold of > or =100 posit

90 Cryptococcal antigenemia (CrAg+) in the absence of CM can represent e

91 s and asymptomatic, subclinical cryptococcal antigenemia (CRAG+) is unknown.

92 ed pregnant women and their newborns, clears antigenemia, crosses the placenta, and exhibits pharmaco

93 Duration of antigenemia decreased in 5 of 7 treated monkeys, 2 havin

94 al fungal pulmonary burden and galactomannan antigenemia demonstrated persistent infection, despite t

95 on-Hodgkin's lymphoma, cytomegalovirus (CMV) antigenemia, diabetes active at the time of the IFI, and

96 Antigenemia-directed valganciclovir as preemptive therap

97 The RRV 50% antigenemia dose was 1.8 x 10(3) PFU, and the 50% diarrh

98 ther rotavirus infection was associated with antigenemia during a major outbreak of gastroenteritis i

99 Elevated p24 antigenemia during the first 6 months of life correlates

100 y dose of HBIg reduces the recurrence of HBs antigenemia, even in patients with indices of active vir

101 acute respiratory infection for cryptococcal antigenemia, even in the absence of meningitis.

102 ns were tested for CMV infection by (i) pp65 antigenemia expression in leukocytes, (ii) the Digene Hy

103 ld be suspected when CMV viremia (DNAemia or antigenemia) fails to improve or continue to increase af

104 f CMV-specific immune reconstitution and CMV antigenemia following SCT.

105 for this finding is the persistence of HRP2 antigenemia following treatment of an acute infection.

106 to assess accuracy of 1,3-beta-d-glucan (BG) antigenemia for diagnosis of IAC.

107 ds as the primary risk factor for increasing antigenemia: for increases greater than or equal to twic

108 More patients in the antigenemia-ganciclovir group developed CMV disease befo

109 andomized at engraftment to receive placebo (antigenemia-ganciclovir group) or ganciclovir (ganciclov

110 ients with CMV disease before day 100 in the antigenemia-ganciclovir group, 10 (8.8%) had disease bef

111 oat of 29 patients, 14 of whom received pp65 antigenemia-guided early ganciclovir treatment and 15 of

112 In the 14 patients who received pp65 antigenemia-guided early treatment, the incidence of PBL

113 who received prophylactic ganciclovir versus antigenemia-guided pre-emptive therapy.

114 e found that individuals who experienced CMV antigenemia had lower tumor necrosis factor-alpha (TNF-a

115 ity of molecular diagnostic techniques (PCR, antigenemia) has resulted in our ability to detect viral

116 endently associated with hepatitis B surface antigenemia (hazard ratio [HR] 9.7, 95% confidence inter

117 50 of 51) of CMV-positive (cell culture- and antigenemia immunofluorescence [AG-IFA]-positive) clinic

118 e immunodiffusion tests detected P.marneffei antigenemia in 10 (58.8%) of 17 patients, whereas the la

119 hereas the latex agglutination test detected antigenemia in 13 (76.5%) of the 17 patients.

120 ay resulted in earlier detection compared to antigenemia in a time-to-event analysis of 42 CMV-seropo

121 into the bloodstream of mice to simulate the antigenemia in cryptococcosis, inhibits PMN accumulation

122 d symptoms independently associated with p24 antigenemia in HIV antibody-seronegative persons include

123 Among the 47 patients with antigenemia increases greater than or equal to twice the

124 sment of viremia and daily assessment of NS1 antigenemia indicated balapiravir did not measurably alt

125 ion of L-FMAU significantly reduced viremia, antigenemia, intrahepatic WHV replication, and intrahepa

126 and people have demonstrated that rotavirus antigenemia is a common event during natural infection.

127 Preemptive therapy guided by pp65 antigenemia is a useful and cost effective strategy for

128 BG antigenemia is superior to Candida score and colonizatio

129 The CMV Brite antigenemia kit was compared with culture and an establi

130 Biotest CMV Brite and the Bartels/Argene CMV Antigenemia kits.

131 The mean decline in the antigenemia level after initiation of valganciclovir and

132 The median reduction in antigenemia level with oral ganciclovir was 55% at week

133 y with R-/D+ CMV serostatus and baseline CMV antigenemia level, regardless of the study group.

134 eek 1, 93% by week 2, and 100% by week 4 had antigenemia levels below the baseline after oral gancicl

135 associated with rising cytomegalovirus (CMV) antigenemia levels during preemptive therapy among stem

136 Overall, rising antigenemia levels were not correlated with CMV disease.

137 eveloped during therapy, however, had rising antigenemia levels.

138 cted animals showed an early spike in plasma antigenemia, maintained high virus burdens, and had sign

139 We describe how CMV antigenemia may be accurately detected by means of human

140 Thus, quantitative CMV pp65 antigenemia may be useful in guiding antiviral treatment

141 l three methods, including 2 with high-grade antigenemia (more than three positive cells in duplicate

142 lasmodium falciparum HRP-2 (PfHRP-2)-related antigenemia (n=6121) following vitamin A supplementation

143 here were 122 samples that were PCR positive-antigenemia negative (specificity, 93%).

144 samples compared to 121 of 122 PCR positive-antigenemia negative samples (P < 0.001).

145 Twenty-three patients remained antigenemia negative throughout the monitoring period, n

146 of three patients with CMV disease who were antigenemia negative were detected by plasma PCR prior t

147 of the 15 patients (242 specimens) who were antigenemia negative were positive for CMV DNA by PCR, a

148 itive-PCR negative) and all 57 (PCR positive-antigenemia negative) could be confirmed at different ti

149 Of 50 patients without CMV antigenemia, none developed CMV disease.

150 Antigenemia occurred in 26 patients (38.8%) a median of

151 ive liver transplant recipients studied, CMV antigenemia occurred in 31% (22 of 72).

152 Antigenemia occurred in 9.3% of patients with non-SCT (n

153 Antigenemia occurred sporadically at low levels (< 5 pos

154 patients who presented with or progressed to antigenemia of > 5 positive cells/slide developed fatal

155 In patients with antigenemia of 3 or more positive cells in 2 slides and/

156 or causing false-positive galactomannan (GM) antigenemia of Plasma-Lyte hydration solution.

157 Thus, the impact of HIV antigenemia on B cells and Tfh cell interactions warrant

158 CMV-related death among patients with rising antigenemia on preemptive therapy.

159 assay was positive less frequently than the antigenemia or Amplicor assays.

160 After 3 months, continued detection of pp65 antigenemia or CMV DNA in plasma or peripheral blood leu

161 nfirmed CMV disease or CMV infection by pp65 antigenemia or CMV DNA PCR compared to maribavir patient

162 ase, nor posttransplantation cytomegalovirus antigenemia or cytomegalovirus disease had statistically

163 say was more likely to be positive at higher antigenemia or viral load levels.

164 immunological mediators that clear rotavirus antigenemia or viremia remain undefined.

165 genetics altered the occurrence of rotavirus antigenemia or viremia.

166 tion (AR) (p = 0.005), cytomegalovirus (CMV) antigenemia (p = 0.005) and lower respiratory tract infe

167 seropositive recipients), trends to less CMV antigenemia (P =.11), viremia (P =.16), and disease (P =

168 al burden (P</=.05), and serum galactomannan antigenemia (P</=.01), compared with either agent alone.

169 CMV DNA (as detected by PCR), but not antigenemia, persisted in patients who later developed r

170 ly treatment, the incidence of PBL PCR, pp65 antigenemia, plasma PCR, and viremia before day 100 was

171 Twenty-three patients were antigenemia positive during the monitoring period, 12 of

172 uld be detected by other methods in 15 of 29 antigenemia positive-PCR negative samples compared to 12

173 On a per-subject basis, 21 of 25 patients (antigenemia positive-PCR negative) and all 57 (PCR posit

174 There were 14 antigenemia-positive patients, 8 of whom developed activ

175 e values compared to antigenemia: 122 of 151 antigenemia-positive samples were detected (sensitivity,

176 ain reaction (qPCR) or phosphoprotein (pp65) antigenemia (pp65emia) for starting preemptive therapy h

177 demonstrated rapid disease, with progressive antigenemia preceding early deaths 90-96 days after inoc

178 therapy with ganciclovir after detection of antigenemia prevented all but one case of CMV disease pr

179 tiviral therapy instituted upon detection of antigenemia prevented tissue invasive CMV in both gancic

180 Untreated low-grade antigenemia progressed to CMV disease in 19% of patients

181 ctively for CMV infection (quantitative pp65 antigenemia, quantitative CMV-DNA, blood culture), T-cel

182 h or without SCT, Asians had the highest CMV antigenemia rates and burdens, followed by blacks, Hispa

183 ng the allogeneic SCT recipients, higher CMV antigenemia rates were also associated with female sex,

184 negative CMV antigenemia and resumed only if antigenemia recurred.

185 n, posaconazole and itraconazole resolved GM antigenemia, reduced residual fungal burden, and improve

186 gher in those subjects who experienced early antigenemia relative to those who did not (2.2% vs 0.33%

187 ithholding prophylaxis in the absence of CMV antigenemia, reliably identified patients in whom no pro

188 ng SHIV infection, a period of intense viral antigenemia, representation of various V(H) families inc

189 Clearance of antigenemia required lymphocytes, but neither T nor B ly

190 Q-PCR results were positive earlier than antigenemia results in 30 (77%) of 39 episodes detected

191 discontinuing ganciclovir based on negative antigenemia results in more CMV disease by day 100 than

192 Rotavirus antigens (antigenemia), RNA, or infectious virus (viremia) has bee

193 parasitemia (RR=0.46, 95% CI=0.39-0.54) and antigenemia (RR=0.23, 95% CI=0.17-0.29).

194 s and was weakly associated with hepatitis B antigenemia, suggesting that persistence of HPV infectio

195 Q-PCR was more sensitive than the antigenemia test and had sufficient specificity for clin

196 of cytomegalovirus (CMV) infection using the antigenemia test has been used to monitor CMV infection

197 as an accurate and robust alternative to the antigenemia test to predict CMV disease and to monitor e

198 PCR and antigenemia test values decreased with anti-CMV therapy.

199 We compared results of the pp65 CMV antigenemia test with quantitative touch-down polymerase

200 ght laboratory assays, viz., the pp65 direct antigenemia test, a quantitative cytomegalovirus (CMV)-s

201 with a greater sensitivity than the standard antigenemia test.

202 outine preemptive therapy guided by the pp65 antigenemia test.

203 4 samples for blood culture, 290 samples for antigenemia testing, and 432 samples for PCR.

204 with 48, 99, 85, and 98%, respectively, for antigenemia testing, and 8, 100, 100, and 97%, respectiv

205 serial cytomegalovirus (CMV) blood culture, antigenemia testing, and qualitative and quantitative pl

206 emia weekly; those with positive findings on antigenemia tests were treated with intravenous ganciclo

207 id tumors had a significantly higher rate of antigenemia than those with myeloid tumors (13.6% versus

208 Among the 808 patients with antigenemia, the circulating peak CMV burden was signifi

209 There was a high correlation between antigenemia values and HCMV loads as determined by the T

210 Antigenemia values of 0, 1 to 10, 11 to 100, 101 to 1,00

211 Corresponding to antigenemia values of 1 to 2, 10, and 50 positive cells

212 Level of antigenemia varied inversely with survival.

213 These findings indicate that antigenemia/viremia occurs routinely in rotavirus infect

214 Antigenemia was associated positively with age in villag

215 In multivariable models, CMV pp65 antigenemia was associated with a decreased risk of rela

216 In univariate analyses, p24 antigenemia was associated with more-rapid progression t

217 Antigenemia was common in this outbreak and might provid

218 Rising antigenemia was confirmed by polymerase chain reaction f

219 Antigenemia was determined in 1322 persons by means of t

220 igh-dose steroids, low-level subclinical CMV antigenemia was found to stimulate both CD4+ and CD8+ fu

221 incidence of CMV infection based on CMV pp65 antigenemia was lower in each of the respective maribavi

222 Antigenemia was monitored weekly after liver transplanta

223 However, CMV antigenemia was more sensitive than culture at all time

224 Antigenemia was observed with homologous and heterologou

225 996 and 2004, surveillance testing using CMV antigenemia was performed at weeks 2, 4, 6, 8, 10, 12, a

226 Human cytomegalovirus antigenemia was the only variable assessed that was asso

227 Man CMV quantitative PCR (QPCR) with the CMV antigenemia was undertaken.

228 atients were prospectively monitored for CMV antigenemia weekly; those with positive findings on anti

229 ior to CMV exposure) on the incidence of CMV antigenemia were determined; and the CMV burdens were qu

230 CD4+ cell counts and antigenemia were measured throughout infection.

231 Alternatively, if antigenemia were monitored serially after transplant, th

232 Surveillance cultures for CMV pp65 antigenemia were performed in all patients at weeks 2, 4

233 Patients with CMV antigenemia were randomized into two study groups.

234 Twenty-two patients with asymptomatic antigenemia were randomized to two study groups.

235 Cryptococcomas and serum antigenemia were slow to resolve.

236 eatures of reactivated cytomegalovirus (CMV) antigenemia were studied among 4,382 cancer patients who

237 allograft recipients, 119 patients with CMV antigenemia were studied.

238 CMV isolates obtained at the time of rising antigenemia were susceptible to ganciclovir, indicating

239 G4) levels (P = 0.0035) were associated with antigenemia, whereas microfilaremia was associated with

240 These findings suggest that the presence of antigenemia, which is an indicator of current active inf

241 positive by PBL PCR, plasma PCR, and/or pp65 antigenemia while receiving ganciclovir; 3 (20%) had bre

242 7/59) of the patients from 2001 to 2004 with antigenemia who received valganciclovir as preemptive th

243 participants (5%) had isolated cryptococcal antigenemia with a negative CSF CRAG and culture, of who

244 roup, the association of hepatitis B surface antigenemia with TCC exit site infection was dependent o

245 (n = 114) was given ganciclovir for CMV pp65 antigenemia without prior acyclovir, and group 3 (n = 13